[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

Pharm Sci Asia ; 34(1),
 

Effect of OVS1 Monoclonal Antibody as Targeted Ovarian and Breast Cancer Therapy

P. Moongkarndi,* N. Jaisupa, S. Jongsomboonkusol, S. Kaslungka, N. Sengpanich, W. Samosorn, N. Kosem and N. Neungton

-


Cancer is ranked among the top three causes of death in Thailand. The research has been focused to improve the diagnosis and treatment of cancers. Monoclonal antibodies could become one of the major tools to achieve the satisfied outcome. OVS1 monoclonal antibody (MAb) produced against ovarian cancer was used to identify the mucinous cystadenocarcinoma antigen as a tumor marker secreted in serum. Since breast and ovarian cancers shared various associate markers, the potential of OVS1 MAb in ovarian and breast cancer treatments was determined. MTT assay was employed to measure the cytotoxicity against breast (BT549), ovarian (SKOV3) and endothelial (ECV304) cell lines. Paclitaxel, an anti-tumor drug, and ?-mangostin, a natural purified constituent from Garcinia mangostana pericarp, were tested as MAb-drug conjugation. The binding efficiency of OVS1-?-mangostin to the cancer cells was monitored by fluorescein-5-isothiocyanate (FITC). Furthermore, the apoptosis of cancer cell lines was examined using fluorimetric assay and confirmed by DNA fragmentation in gel electrophoresis. The ED50 of ?-mangostin were 3.5 and 3.4 µg/ml, while the ED50 of MAb-?-mangostin conjugation (MAb-drug conjugation) were 29.6 and 42.8 µg/ml against SKOV3 and ECV304, respectively. Although the ED50 of MAb-drug (?-mangostin) conjugation was higher than that of ?-mangostin alone, the binding efficiency and specificity of MAb-?-mangostin to SKOV3 cancer cells were satisfactory as monitored using FITC. Furthermore, the ED50 of MAb-?-mangostin conjugation against SKOV3 cancer cell showed significant lower value than that against ECV304 endothelial cell line. This study supported the potential application of MAb-drug or


Keyword:

MAb-drug conjugation, α-mangostin, OVS1 MAb, paclitaxel, targeted cancer therapy




Download full paper (PDF File size: 255.90 KB.)





Vol.34
No.1-4
2007

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University



Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2024
    Faculty of Pharmacy, Mahidol University, THAILAND
 

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.